dc.contributor.author | UYGUNOĞLU, UĞUR | |
dc.contributor.author | Asan, Furkan | |
dc.contributor.author | Siva, Aksel | |
dc.contributor.author | GÜNDÜZ, AYŞEGÜL | |
dc.contributor.author | TÜTÜNCÜ, MELİH | |
dc.contributor.author | SAİP, Sabahattin | |
dc.contributor.author | SAVRUN, Feray | |
dc.date.accessioned | 2023-02-21T09:57:42Z | |
dc.date.available | 2023-02-21T09:57:42Z | |
dc.date.issued | 2022 | |
dc.identifier.citation | Asan F., GÜNDÜZ A., TÜTÜNCÜ M., UYGUNOĞLU U., SAVRUN F., SAİP S., Siva A., "Treatment of multiple sclerosis-related trigeminal neuralgia with onabotulinumtoxinA", HEADACHE, cilt.62, sa.10, ss.1322-1328, 2022 | |
dc.identifier.issn | 0017-8748 | |
dc.identifier.other | vv_1032021 | |
dc.identifier.other | av_38f52e6a-c5c0-472b-9584-780d11794b8e | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/187963 | |
dc.identifier.uri | https://doi.org/10.1111/head.14414 | |
dc.description.abstract | BackgroundThe effectiveness of onabotulinumtoxinA (BTX-A) has been established in primary trigeminal neuralgia (TN). However, to the best of our knowledge, the efficacy of BTX-A in secondary TN has not yet been studied. ObjectiveThis study aimed to investigate the efficacy of BTX-A treatment in patients with multiple sclerosis-related trigeminal neuralgia (TN-MS) and compare the efficacy of BTX-A treatment between patients with primary trigeminal neuralgia (TN-P) and patients with TN-MS. MethodsThis was a retrospective medical record-review study. Demographic and clinical features and severity and frequency of pain before and 2 weeks after the BTX-A administration were extracted from the patient files. BTX-A was injected into the painful area subcutaneously and/or submucosally. BTX-A injections were performed by the same physician using the same methods. A reduction in severity and/or frequency of pain >= 50% was considered therapeutic efficacy. ResultsFifty-three patients were included in this study. We classified 22 (42%) as TN-P and 31 (58%) as TN-MS. Treatment with BTX-A was effective in 16 of 31 (52%) patients with TN-MS and 10 of 22 (45%) with TN-P. BTX-A treatment was less effective in patients with a history of interventional treatments and more effective in patients with concomitant continuous pain (p = 0.007; odds ratio [OR]: 0.020-0.53 and p = 0.047; OR: 0.046-0.98, respectively). ConclusionThe BTX-A treatment was found to be effective in at least half of our cohort with TN-MS. Concomitant continuous pain and history of interventional treatments to the trigeminal nerve or ganglion might be predictive factors for the efficacy of BTX-A treatment. | |
dc.language.iso | eng | |
dc.subject | Nöroloji (klinik) | |
dc.subject | Yaşam Bilimleri | |
dc.subject | Tıp | |
dc.subject | Klinik Tıp (MED) | |
dc.subject | Klinik Tıp | |
dc.subject | KLİNİK NÖROLOJİ | |
dc.subject | Sağlık Bilimleri | |
dc.subject | Nöroloji | |
dc.subject | Dahili Tıp Bilimleri | |
dc.title | Treatment of multiple sclerosis-related trigeminal neuralgia with onabotulinumtoxinA | |
dc.type | Makale | |
dc.relation.journal | HEADACHE | |
dc.contributor.department | İstanbul Üniversitesi-Cerrahpaşa , , | |
dc.identifier.volume | 62 | |
dc.identifier.issue | 10 | |
dc.identifier.startpage | 1322 | |
dc.identifier.endpage | 1328 | |
dc.contributor.firstauthorID | 4087945 | |